FGFR2-targeted therapy — the biomarker-driven treatment paradigm where pemigatinib demonstrated a 42% reduction in disease progression risk versus standard chemotherapy in the Phase 3 FIGHT-302 trial, establishing the first potential first-line targeted therapy for FGFR2 fusion-positive cholangiocarcinoma — creates the most clinically transformative market dynamic, with the...